All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2023-06-28T09:24:11.000Z

First-in human-trial of revumenib in patients with KMT2A-rearranged or NPM1-mutated leukemia

Jun 28, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

Bookmark this article

Introduction

Lysine methyltransferase 2A rearrangements (KMT2Ar) and nucleophosmin 1 gene (NPM1) mutations arise in 80% of pediatric patients with acute lymphoblastic leukemia and ~30% of adult patients with acute myeloid leukemia. Revumenib, a potent selective oral inhibitor of the menin–KMT2A interaction, prevents the assembly of oncogenic KMT2A wild-type or fusion complexes on chromatin and has demonstrated significant anti-leukemic activity in preclinical KMT2Ar or NPM1-mutated leukemia models.

Currently, there are no targeted therapies specifically approved for acute leukemia with KTM2A or NPM1 mutations. Below, we summarize an article by Issa et al.1 published in Nature on a first-in-human trial investigating the efficacy and safety of revumenib in patients with KMT2A-rearranged or NPM1-mutated relapsed/refractory (R/R) acute leukemia.

Study design

This is a phase I, multicenter, open-label dose-escalation study conducted across nine sites in the United States. Included patients were

  • aged 1–79;
  • had received a median of four previous lines of therapy; and
  • had R/R acute leukemia with KTM2A rearrangements or mutated NPM1.

The study consisted of two parallel dose escalation cohorts of patients, with revumenib administered orally every 12 hours in continuous 28-day cycles (Figure 1). Primary endpoints included safety, maximum tolerated dose, recommended phase II dose, and characterization of the pharmacokinetic parameters of revumenib based on CYP3Ai. Exploratory endpoints included assessment of anti-leukemic activity in patients treated with KMT2Ar or mutated NPM.

Figure 1. Trial design*

CYP3A4i, cytochrome P450 3A4 inhibitor; KMT2A, Lysine methyltransferase 2A; KMT2Ar, KMT2A rearranged; NPM1, nucleophosmin 1; q12h, every 12 hours; R/R, relapsed/refractory.
*Adapted from Issa, et al.1

Results

At the data cutoff (March 31, 2022), a total of 68 patients were treated, 82% of whom had R/R acute myeloid leukemia, 16% had acute lymphoblastic leukemia, and 2% had mixed-phenotype acute leukemia. Additionally, 46% had KMT2Ar, 21% had mutated NPM1, and 12% had neither mutation. Baseline characteristics are summarized in Table 1.

Table 1. Baseline characteristics*

Characteristic, % (unless otherwise stated)

Whole cohort (N = 68)

Median age, years

42.5

Male

38

Female

62

Median bone marrow blasts

59.5

Acute leukemia type

 

               AML

82

               Therapy-related AML

10

               ALL

16

               MPAL

2

Genotype

 

               KMT2Ar

68

               t(9;11)(p21;q23)

15

               t(4;11)(q21;p23)

9

               t(11;19)(q23;p13.1)

7

               t(11;19)(q23;p13.3)

6

               t(6;11)(q27;q23)

4

               t(11;17)(q23;q12)

3

               Other 11q23 translocations

24

               Mutated NPM1

21

               KMT2Ar and NPM1 wild type

12

Co-occurring mutations

 

               FLT3

25

               RAS

29

               TP53

10

Previous therapies

 

               Median number of prior therapies (range), n

4 (1–12)

               Venetoclax

60

               Allogeneic HSCT

46

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; FLT3, FMS-like tyrosine kinase 3; HSCT, hematopoietic stem cell therapy; KMT2A, histone-lysine N-methyltransferase 2A; MPAL, mixed-phenotype acute leukemia; NPM1, nucleophosmin 1; RAS, renin-angiotensin-system; TP53, tumor protein 53.
*Adapted from Issa, et al.1

Safety

Among the treated cohort, 67 patients (99%) experienced any-grade treatment-emergent adverse events (TEAE), and 53 (78%) had any-grade treatment-related adverse event (TRAE).

The most common any-grade TEAEs were prolongation of the QT interval, nausea, vomiting and febrile neutropenia; the incidence of the most common TEAE’s occurring in ≥20% of patients are reported in Figure 2.

Figure 2. Most common TEAEs (occurring in ≥20% of patients)* 

ALT, alanine transaminase; ECG, electrocardiogram; TEAE, treatment-emergent adverse event.
*Adapted from Issa, et al.1

  • The most common Grade 3 treatment-related adverse event was the prolongation of the QT interval, occurring in nine patients; all were able to continue treatment at the next lower dose level.
  • No treatment-related adverse events led to death or discontinuation of revumenib.
  • Grade 2 differentiation syndrome was reported in 11 patients and all cases were resolved following corticosteroid treatment.

Pharmacokinetics and efficacy

  • Doses of 226 mg and 276 mg every 12 hours in Arm A met the safety, tolerability, and pharmacokinetic prespecified criteria for the recommended phase II dose.
  • Doses of 113 mg and 163 mg every 12 hours met the same prespecified criteria in Arm B.
  • The overall response rate in efficacy-evaluable patients was 53% (n = 60).
  • The rate of complete remission or complete remission with partial hematologic recovery was 30%, 78% of whom achieved undetectable minimal residual disease.

Conclusion

This study highlights that menin inhibition with revumenib monotherapy has encouraging anti-leukemic activity and safety in both children and adults with relapsed/refractory KMT2Ar or NPM1 mutated leukemia. Revumenib induced complete remissions and was associated with low Grade 3 or higher treatment-emergent adverse events.

  1. Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. 2023;615(7954):920-926. DOI: 10.1038/s41586-023-05812-3

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
5 votes - 57 days left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox